CS1 increases the production of t-PA

Healthy blood vessels have a built-in sprinkler system in the cells which form the inside wall of the vessel that quickly act to limit the growth of a developing blood clot by showering the thrombolytic protein t-PA on the clot. This normally protective sprinkler system for endogenous fibrinolysis often works very badly in many individuals with a high risk of thrombosis due to lack of access to t-PA. This is due to a reduced production of t-PA and / or elevated levels of PAI-1. Furthermore, these individuals also often have elevated levels of PAI-1 which disables the function of t-PA. The drug CS1 normalizes both of these factors and Cereno Scientific’s discovery represents a new way of attack to restore the body’s natural defense against dangerous blood clots.

Research data that indirectly supports this has been previously published by two completely independent research groups. A group of researchers in Denmark1 reported in 2011 that patients who were on treatment for epilepsy and treated with valproic acid (VPA), noted for about 40 percent fewer heart attacks. An Irish research group2 published in 2014 that they had seen similar indications of the protective effect of valproic acid on the Irish population. Both of these studies were large retrospective epidemiological studies.

Preclinical studies have clearly demonstrated that HDAC inhibitors such as valproic acid are potent in low doses to increase production of t-PA3 and thus leads to an increased thrombosis protection. The effects demonstrated in population studies above indicate a possible heart and brain-protective effect of valproic acid which, based on Cereno Scientific’s concepts, could be explained by increased and improved activity in the body’s protective defense against blood clots. The company has in its own studies shown that preventive treatment with valproic acid causes an increase in t-PA production in the vascular wall cells, thus restoring the t-PA synthesis and thus the ability of the natural rapid clot lysis ability to be activated only locally in the blood vessel when a blood clot is being formed. Cereno Scientific has also been found that valproic acid reduces clot formation in vivo .

Sources:

  1. Olesen et al, Pharmacoepidemiol drog Saf 2011
  2. Dregan et al, Pharmacoepidemiol drog Saf 2014
  3. Larsson et al PLoS One 2012, Larsson et al J Thromb trombolys 2013

 

Calendar

BioStock Life Science Summit 2019-10-23 - 2019-10-24

3rd annual Anti-Fibrotic Drug Development Summit (AFDD) 2019-11-18 - 2019-11-20

Nordic-American Life Sciences Conference 2019-12-04 - 2019-12-05

16th Global Cardiovascular Clinical Trialists Forum 2019-12-05 - 2019-12-07

More about us...

Subscribe for corporate news

Follow us on LinkedIn

Follow us on Twitter

Privacy policy

We are proud supporters of World Thrombosis Day. Read more